Medicaid Gross Spending On 10 Selected Diabetes & 2 Selected Weight Loss Drugs Totaled More Than $9 Billion In 2023, An Increase Of 540% From 2019

On December 18, 2024, the U.S. Department of Health and Human Services Office of Inspector General (OIG) published this report which found that Medicaid gross spending on 10 selected diabetes and two selected weight loss drugs totaled more than $9 billion in 2023, an increase of 540% from 2019. The goal of the report was to identify national Medicaid gross spending on and utilization of selected diabetes and weight loss drugs that occurred during the audit period . . .